Try our mobile app

Switch to company model in "Rising Stars" logic    *

General information

Country: UNITED STATES

Sector: Diagnostics and Research

Natera, Inc. operates as a diagnostics company. The Company provides preconception and prenatal genetic testing services. Natera also offers pre-implantation genetic diagnosis, aneuploidy screening, translocation, and single gene testing services.
Website: natera.com


  • Good financial results growth rate 20.0% (average between last period year over year growth for revenue and EBITDA), there is slowdown compared to average historical growth rates (20.7%)
  • Dividend yield for the last twelve months 0.0%
  • Free cash flow yield 1.9% (LTM)
  • Share price is 464.2% higher than minimum and 13.4% lower than maximum for the last 3 years
  • The company is overvalued by EV / LTM EBITDA multiple compared to target level (500.0x vs 30.0x)
  • For the last 3 months insiders sold company shares on $53.8 mln (-0.281% of cap.)

Key Financials (Download financials)

Ticker: NTRA
Share price, USD:  (-0.4%)211.85
year average price 204.32  


year start price 165.51 2025-06-05

min close price 133.66 2025-07-31

max close price 244.55 2025-12-05

current price 211.85 2026-06-04
Common stocks: 98 408 000

Dividend Yield:  0.0%
EV / Sales: 8.6x
Margin (EBITDA LTM / Revenue): -12.3%

Target EV / EBITDA (hist percentile): 30.0x
Express share price potential:
EV / LTM EBITDA mutiple calculation
Market Cap ($m): 20 848
Net Debt ($m): -900
EV (Enterprise Value): 19 948
EBITDA LTM (млн $): -283
Price to Book: 16.7x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / EBITDA

Potential dynamics

News


2026-01-13seekingalpha.com

Natera, Inc. (NTRA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

2026-01-13zacks.com

NTRA & NVDA Partner to Improve AI Models for Precision Medicine

2025-12-05benzinga.com

Why Is Adaptive Biotechnologies Stock Trading Lower After Natera's Over $400 Million Deal?

2025-11-19seekingalpha.com

Natera, Inc. (NTRA) Presents at Jefferies London Healthcare Conference 2025 Transcript

2025-11-06seekingalpha.com

Natera, Inc. (NTRA) Q3 2025 Earnings Call Transcript

2025-11-06zacks.com

Here's What Key Metrics Tell Us About Natera (NTRA) Q3 Earnings

2025-11-06zacks.com

Natera (NTRA) Reports Q3 Loss, Beats Revenue Estimates

2025-10-27businesswire.com

Halper Sadeh LLC Encourages Natera Inc. Shareholders to Contact the Firm to Discuss Their Rights

2025-10-20businesswire.com

Successful IMvigor011 Trial Achieves 41% Improvement in Overall Survival for Bladder Cancer Patients

2025-10-12businesswire.com

Natera to Present 14 Studies at ESMO, Including IMvigor011 Oral Presentation in Presidential Symposium
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol NTRA NTRA NTRA NTRA NTRA NTRA NTRA NTRA NTRA NTRA NTRA NTRA NTRA NTRA
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2025-11-07 2025-08-08 2024-11-12 2024-08-09 2024-05-10 2023-11-09 2023-08-04 2023-05-10 2022-11-09
acceptedDate 2025-11-06 20:02:44 2025-08-07 20:24:04 2025-02-27 21:43:05 2024-11-12 16:23:00 2024-08-08 20:28:12 2024-05-09 20:29:48 2024-02-28 21:10:14 2023-11-08 20:15:16 2023-08-03 19:37:07 2023-05-09 20:46:49 2023-03-01 06:05:02 2022-11-08 21:22:49 2022-02-24 21:13:07 2021-02-25 21:55:00
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
revenue 592M 547M 1 697M 440M 413M 368M 1 083M 268M 261M 242M 820M 211M 625M 391M
costOfRevenue 208M 200M 674M 168M 170M 159M 590M 147M 143M 148M 456M 117M 318M 204M
grossProfit 384M 347M 1 023M 272M 243M 209M 493M 121M 118M 94M 364M 94M 307M 187M
grossProfitRatio 0.649 0.635 0.618 0.588 0.567 0.451 0.452 0.387 0.447
researchAndDevelopmentExpenses 173M 146M 404M 97M 89M 89M 321M 77M 78M 82M 316M 66M 264M 100M
generalAndAdministrativeExpenses 0 0 0 0 0 0 0 0 0 0 0 0 0 0
sellingAndMarketingExpenses 0 0 0 0 0 0 0 0 0 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 309M 311M 841M 214M 198M 194M 618M 155M 153M 150M 589M 148M 511M 304M
otherExpenses 0 465 000 0 0 0 307 000 0 349 000 341 000 370 000 0 0 0 0
operatingExpenses 482M 457M 1 245M 311M 287M 283M 939M 232M 231M 232M 905M 213M 775M 404M
costAndExpenses 690M 657M 1 919M 479M 457M 442M 1 529M 379M 374M 380M 1 361M 330M 1 094M 607M
interestIncome 0 11M 43M 12M 10M 10M 24M 5M 5M 5M 4M 87 000 5M 8M
interestExpense 1M 1M 11M 3M 3M 3M 13M 3M 3M 3M 9M 2M 8M 15M
depreciationAndAmortization 10M 10M 31M 8M 8M 11M 39M 5M 5M 5M 30M 5M 11M 9M
ebitda -76M -90M -148M -20M -26M -64M -383M -106M -108M -134M -507M -114M -452M -206M
ebitdaratio -0.129 -0.164 -0.044 -0.062 -0.173 -0.393 -0.413 -0.553 -0.54
operatingIncome -98M -110M -222M -39M -44M -74M -446M -111M -112M -138M -541M -119M -468M -216M
operatingIncomeRatio -0.165 -0.202 -0.089 -0.106 -0.202 -0.414 -0.43 -0.572 -0.565
totalOtherIncomeExpensesNet 10M 10M 33M 8M 7M 7M 12M 2M 1M 2M -6M -2M -3M -13M
incomeBeforeTax -87M -101M -190M -31M -37M -67M -435M -109M -111M -137M -547M -121M -471M -230M
incomeBeforeTaxRatio -0.147 -0.184 -0.07 -0.088 -0.183 -0.406 -0.425 -0.566 -0.576
incomeTaxExpense 207 000 275 000 695 000 730 000 892 000 428 000 271 000 202 000 -282 000 160 000 978 000 185 000 618 000 98 000
netIncome -88M -101M -190M -32M -37M -68M -435M -109M -111M -137M -548M -121M -472M -230M
netIncomeRatio -0.148 -0.185 -0.072 -0.091 -0.184 -0.406 -0.424 -0.566 -0.577
eps -0.64 -0.74 -1.53 -0.26 -0.3 -0.56 -3.78 -0.95 -0.97 -1.23 -5.57 -1.25 -5.21 -2.84
epsdiluted -0.64 -0.74 -0.26 -0.3 -0.56 -0.95 -0.97 -1.23 -1.25
weightedAverageShsOut 137M 136M 125M 124M 123M 121M 115M 115M 114M 112M 98M 97M 91M 81M
weightedAverageShsOutDil 137M 136M 125M 124M 123M 121M 115M 115M 114M 112M 98M 97M 91M 81M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-02-28 2024-02-29 2023-03-01 2022-02-25 2021-02-26
fiscalYear 2024 2023 2022 2021 2020
netInterestIncome 33M 12M -6M -3M -8M
ebit -179M -422M -538M -463M -215M
nonOperatingIncomeExcludingInterest -43M -24M -4M -5M -2M
netIncomeFromContinuingOperations -190M -435M -548M -472M -230M
netIncomeFromDiscontinuedOperations 0 0 0 0 0
otherAdjustmentsToNetIncome 0 0 0 0 0
netIncomeDeductions 0 0 0 0 0
bottomLineNetIncome -190M -435M -548M -472M -230M
epsDiluted -1.53 -3.78 -5.57 -5.21 -2.84

Balance Sheet Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol NTRA NTRA NTRA NTRA NTRA NTRA NTRA NTRA NTRA NTRA NTRA NTRA NTRA NTRA
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2025-11-07 2025-08-08 2024-11-12 2024-08-09 2024-05-10 2023-11-09 2023-08-04 2023-05-10 2022-11-09
acceptedDate 2025-11-06 20:02:44 2025-08-07 20:24:04 2025-02-27 21:43:05 2024-11-12 16:23:00 2024-08-08 20:28:12 2024-05-09 20:29:48 2024-02-28 21:10:14 2023-11-08 20:15:16 2023-08-03 19:37:07 2023-05-09 20:46:49 2023-03-01 06:05:02 2022-11-08 21:22:49 2022-02-24 21:13:07 2021-02-25 21:55:00
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
cashAndCashEquivalents 1 041M 1 000M 946M 893M 797M 814M 642M 669M 381M 403M 466M 57M 84M 49M
shortTermInvestments 1 000 000 16M 23M 29M 90M 69M 237M 268M 355M 409M 432M 464M 830M 689M
cashAndShortTermInvestments 1 042M 1 016M 968M 922M 887M 883M 879M 937M 736M 812M 898M 521M 914M 737M
netReceivables 286M 309M 314M 307M 336M 289M 278M 255M 260M 247M 244M 236M 122M 79M
inventory 65M 54M 45M 49M 41M 43M 41M 42M 43M 41M 35M 40M 27M 20M
otherCurrentAssets 54M 52M 49M 45M 38M 47M 61M 33M 27M 30M 34M 32M 228 000 187 000
totalCurrentAssets 1 447M 1 432M 1 376M 1 323M 1 302M 1 261M 1 259M 1 267M 1 066M 1 129M 1 212M 830M 1 093M 863M
propertyPlantEquipmentNet 303M 284M 248M 230M 186M 180M 168M 163M 165M 170M 164M 161M 125M 55M
goodwill 0 0 0 0 0 0 0 0 0 0 0 0 0 0
intangibleAssets 0 0 0 0 0 0 0 0 0 0 0 0 0 0
goodwillAndIntangibleAssets 0 0 0 0 0 0 0 0 0 0 0 0 0 0
longTermInvestments 0 0 0 0 0 0 0 0 0 0 0 0 0 0
taxAssets 0 0 0 0 0 0 0 0 0 0 0 0 0 0
otherNonCurrentAssets 71M 41M 37M 38M 29M 26M 15M 16M 18M 19M 18M 18M 19M 15M
totalNonCurrentAssets 374M 325M 285M 268M 215M 207M 183M 179M 182M 189M 183M 179M 143M 69M
otherAssets 0 0 0 0 0 1 0 0 0 0 0 0 0 0
totalAssets 1 821M 1 757M 1 661M 1 591M 1 517M 1 468M 1 442M 1 447M 1 248M 1 319M 1 394M 1 009M 1 236M 932M
accountPayables 46M 37M 35M 28M 33M 26M 15M 21M 21M 36M 31M 34M 27M 8M
shortTermDebt 80M 93M 80M 90M 93M 92M 80M 80M 80M 80M 80M 56M 50M 50M
taxPayables 0 7M 4M 5M 4M 4M 4M 6M 5M 5M 4M 2M 2M 2M
deferredRevenue 22M 22M 20M 18M 18M 18M 17M 15M 16M 17M 11M 8M 7M 50M
otherCurrentLiabilities 293M 226M 73M 160M 166M 170M 69M 173M 160M 158M 63M 169M 58M 48M
totalCurrentLiabilities 442M 385M 344M 301M 315M 306M 307M 290M 277M 291M 310M 267M 219M 199M
longTermDebt 104M 103M 0 386M 345M 283M 283M 351M 353M 356M 282M 360M 280M 202M
deferredRevenueNonCurrent 23M 23M 25M 26M 21M 21M 19M 21M 22M 22M 20M 20M 21M 23M
deferredTaxLiabilitiesNonCurrent 0 0 0 0 0 0 0 283M 282M 0 0 0 0 0
otherNonCurrentLiabilities 0 0 0 0 0 64M 0 -283M -282M 0 0 282M 1M 320 000
totalNonCurrentLiabilities 127M 126M 121M 411M 366M 368M 369M 372M 375M 377M 378M 380M 364M 247M
otherLiabilities 0 0 0 0 0 0 0 0 0 0 0 0 0 0
capitalLeaseObligations 104M 116M 107M 10M 74M 64M 79M 68M 71M 74M 84M 85M 67M 29M
totalLiabilities 569M 511M 465M 712M 680M 674M 676M 662M 652M 668M 689M 647M 583M 446M
preferredStock 0 0 0 0 0 0 0 0 0 0 0 0 0 0
commonStock 14 000 14 000 12 000 12 000 12 000 12 000 11 000 11 000 11 000 11 000 11 000 10000 10000 9000
retainedEarnings -2 823M -2 736M -2 568M -2 514M -2 482M -2 445M -2 377M -2 299M -2 190M -2 080M -1 943M -1 800M -1 395M -929M
accumulatedOtherComprehensiveIncomeLoss -186 999 -287 000 -344 000 -765 000 -1M -2M -3M -5M -9M -12M -16M -20M -2M 4M
othertotalStockholdersEquity 4 076M 3 982M 3 393M 3 320M 3 241M 3 089M 2 796M 2 742M 2 181M
totalStockholdersEquity 1 252M 1 246M 1 195M 879M 837M 794M 765M 785M 596M 651M 706M 362M 653M 486M
totalEquity 1 252M 1 246M 1 195M 879M 837M 794M 765M 785M 596M 651M 706M 362M 653M 486M
totalLiabilitiesAndStockholdersEquity 1 821M 1 757M 1 591M 1 517M 1 468M 1 447M 1 248M 1 319M 1 009M
minorityInterest 0 0 0 0 0 0 0 0 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 1 821M 1 757M 1 661M 1 591M 1 517M 1 468M 1 442M 1 447M 1 248M 1 319M 1 394M 1 009M 1 236M 932M
totalInvestments 1 000 000 16M 23M 29M 90M 69M 237M 268M 355M 409M 432M 464M 830M 689M
totalDebt 185M 196M 187M 476M 438M 440M 442M 431M 434M 436M 446M 416M 397M 281M
netDebt -857M -804M -758M -417M -359M -374M -200M -237M 53M 33M -20M 359M 313M 232M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-02-28 2024-02-29 2023-03-01 2022-02-25 2021-02-26
fiscalYear 2024 2023 2022 2021 2020
accountsReceivables 314M 278M 244M 122M 79M
otherReceivables 0 0 0 0 0
prepaids 0 0 0 30M 27M
totalPayables 39M 19M 35M 29M 10M
otherPayables 4M 4M 4M 2M 2M
accruedExpenses 121M 111M 113M 68M 34M
capitalLeaseObligationsCurrent 10M 12M 8M 6M 7M
capitalLeaseObligationsNonCurrent 97M 67M 77M 61M 21M
treasuryStock 0 0 0 0 0
additionalPaidInCapital 3 764M 3 146M 2 665M 2 050M 1 411M
otherTotalStockholdersEquity 0 0 0 0 0

Cash Flow Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol NTRA NTRA NTRA NTRA NTRA NTRA NTRA NTRA NTRA NTRA NTRA NTRA NTRA NTRA
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2025-11-07 2025-08-08 2024-11-12 2024-08-09 2024-05-10 2023-11-09 2023-08-04 2023-05-10 2022-11-09
acceptedDate 2025-11-06 20:02:44 2025-08-07 20:24:04 2025-02-27 21:43:05 2024-11-12 16:23:00 2024-08-08 20:28:12 2024-05-09 20:29:48 2024-02-28 21:10:14 2023-11-08 20:15:16 2023-08-03 19:37:07 2023-05-09 20:46:49 2023-03-01 06:05:02 2022-11-08 21:22:49 2022-02-24 21:13:07 2021-02-25 21:55:00
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
netIncome -88M -101M -190M -32M -37M -68M -435M -109M -111M -137M -548M -121M -472M -230M
depreciationAndAmortization 10M 10M 31M 5M 8M 11M 24M 7M 5M 5M 17M 5M 11M 9M
deferredIncomeTax 0 0 0 0 0 0 0 479 000 663 000 0 0 0 0 0
stockBasedCompensation 91M 93M 274M 71M 67M 64M 192M 58M 44M 41M 152M 40M 115M 50M
changeInWorkingCapital 41M 31M 2M -2M -38M 19M -48M 10M -22M 2M -83M -32M -46M -39M
accountsReceivables 23M 9M -36M 29M -47M -10M -34M 5M -13M -2M -122M -29M -44M -26M
inventory -10M -4M -4M -8M 2M -2M -5M 612 000 -2M -5M -8M -10M -7M -7M
accountsPayables 5M 5M 13M -6M 6M 11M -15M 67 000 -15M 6M 5M 6M 19M -118 000
otherWorkingCapital 23M 21M 29M -18M 1M 21M 7M 5M 8M 4M 42M 851 000 -14M -6M
otherNonCashItems 5M 4M 19M 10M 4M 88M 20M 4M 4M 8M 30M 6M 56M 28M
netCashProvidedByOperatingActivities 59M 38M 136M 52M 4M 27M -247M -30M -78M -81M -432M -102M -335M -183M
investmentsInPropertyPlantAndEquipment -22M -26M -66M -16M -12M -20M -39M -9M -9M -12M -48M -12M -41M -20M
acquisitionsNet 0 0 0 10M 0 -10M 0 0 0 0 0 0 0 0
purchasesOfInvestments 0 0 -125M -123M 0 0 -98M 0 0 0 -87M -7M -876M -685M
salesMaturitiesOfInvestments 15M 2M 339M 111M 52M 169M 306M 90M 56M 27M 465M 86M 720M 373M
otherInvestingActivites -13M 0 60M -73M -10M 0 0 0 0
netCashUsedForInvestingActivites -20M -24M 43M -32M 138M 81M 47M 16M 67M
debtRepayment 0 0 0 0 0 0 0 0 0
commonStockIssued 0 13M 7M 11M 6M 235M 9M 2M 0
commonStockRepurchased 0 0 0 9M 0 0 0 0 9M 0 0 0 0 0
dividendsPaid 0 0 0 0 0 0 0 0 0
otherFinancingActivites 2M 0 2M 11M -18M -235M -9M 0 1M
netCashUsedProvidedByFinancingActivities 2M 13M 2M 11M 6M 236M 9M 2M 1M
effectOfForexChangesOnCash 0 0 0 0 0 0 0 -103M -36M 0 0 0 0 0
netChangeInCash 41M 26M 303M 96M -17M 172M 176M 288M -22M -63M 381M -34M 36M -13M
cashAtEndOfPeriod 1 041M 1 000M 946M 893M 797M 814M 642M 669M 381M 403M 466M 57M 85M 49M
cashAtBeginningOfPeriod 1 000M 974M 642M 797M 814M 642M 466M 381M 403M 466M 85M 91M 49M 62M
operatingCashFlow 59M 38M 136M 52M 4M 27M -247M -30M -78M -81M -432M -102M -335M -183M
capitalExpenditure -35M -26M -66M -16M -12M -20M -39M -9M -9M -12M -48M -12M -41M -20M
freeCashFlow 24M 12M 69M 35M -8M 7M -286M -39M -87M -92M -479M -114M -376M -202M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-02-28 2024-02-29 2023-03-01 2022-02-25 2021-02-26
fiscalYear 2024 2023 2022 2021 2020
otherInvestingActivities -10M 0 0 -9M 0
netCashProvidedByInvestingActivities 138M 168M 330M -205M -331M
netDebtIssuance -82 000 0 30M 0 200M
longTermNetDebtIssuance -82 000 0 30M 0 200M
shortTermNetDebtIssuance 0 0 0 0 0
netStockIssuance 30M 254M 453M 576M 301M
netCommonStockIssuance 30M 254M 453M 576M 301M
commonStockIssuance 30M 254M 453M 576M 301M
netPreferredStockIssuance 0 0 0 0 0
netDividendsPaid 0 0 0 0 0
commonDividendsPaid 0 0 0 0 0
preferredDividendsPaid 0 0 0 0 0
otherFinancingActivities 0 0 0 0 0
netCashProvidedByFinancingActivities 30M 254M 483M 576M 501M
incomeTaxesPaid 1M 295 000 549 000 283 000 67 000
interestPaid 8M 11M 8M 7M 3M

Earning call transcript

2025 q3
2025-11-06 ET (fiscal 2025 q3)
2025 q2
2025-08-07 ET (fiscal 2025 q2)
2025 q1
2025-05-08 ET (fiscal 2025 q1)
2024 q4
2025-02-28 ET (fiscal 2024 q4)
2024 q3
2024-11-12 ET (fiscal 2024 q3)
2024 q2
2024-08-09 ET (fiscal 2024 q2)
2024 q1
2024-05-09 ET (fiscal 2024 q1)
2023 q4
2024-02-28 ET (fiscal 2023 q4)
2023 q3
2023-11-08 ET (fiscal 2023 q3)
2023 q2
2023-08-03 ET (fiscal 2023 q2)
2023 q1
2023-05-09 ET (fiscal 2023 q1)
2022 q4
2023-02-28 ET (fiscal 2022 q4)
2022 q3
2022-11-08 ET (fiscal 2022 q3)
2022 q2
2022-08-06 ET (fiscal 2022 q2)
2022 q1
2022-05-08 ET (fiscal 2022 q1)

Press-releases

Show financial reports only

2026-05-07 20:05 ET
Natera Reports First Quarter 2026 Financial Results
2026-04-30 12:00 ET
Natera to Report its First Quarter Results on May 7, 2026
2026-04-22 13:00 ET
Prospera™ Evidence in Heart and Lung Transplantation Featured Across 17 Presentations at ISHLT
2026-04-13 ET
Natera Highlights Positive Interim Futility Analysis from Allogene Therapeutics’ MRD-Guided ALPHA3 Trial in Large B-Cell Lymphoma
2026-04-09 ET
Judge Awards 30% Ongoing Royalty to Natera for its MRD-Related Patents
2026-04-07 ET
20 Abstracts at AACR Highlight Scale, Innovation and Clinical Impact of Natera’s Oncology Platform
2026-03-31 ET
SignateraTM MRD Identifies Breast Cancer Patients Who Can Forgo Surgery
2026-03-16 ET
Two Publications Highlight Clinical Utility of Signatera™ in Anal and Rectal Cancers
2026-03-12 ET
Natera Announces Commercial Launch of Zenith™ Genomics for Rare Disease Diagnosis
2026-03-12 ET
MyOme Debuts Zenith™ Portfolio with Natera and Launches Long-Read Methylation Analysis at ACMG 2026
2026-02-27 ET
Signatera™ MRD Data at ASCO GU Highlights Potential Utility Across GU Cancers, Including for Bladder Preservation
2026-02-26 ET
Natera Reports Fourth Quarter and Full Year 2025 Financial Results
2026-02-24 ET
Successful Readout of Prospective Phase 2 SINERGY Trial Supports SignateraTM MRD-Guided Treatment in Head and Neck Cancer
2026-02-17 14:00 ET
Natera to Report its Fourth Quarter and Full Year Results on February 26, 2026
2026-02-06 11:00 ET
Natera Launches EDEN Study on Early Risk Assessment for Preeclampsia and Adverse Pregnancy Outcomes
2026-02-02 ET
Natera Submits Signatera™ CDx PMA to FDA
2026-01-28 ET
Natera Announces Completion of Enrollment in Randomized ACES-EMB Trial in Heart Transplantation
2026-01-26 ET
Prospera™ Featured in Landmark Interventional Study Advancing Lung Transplant Care
2026-01-21 ET
Natera Publishes Clinical Validation of Latitude™ Tissue-Free MRD Test in Colorectal Cancer
2026-01-20 ET
Natera’s Fetal Focus™ Single Gene NIPT (sgNIPT) Selected for Prestigious Oral Plenary Presentation at Society of Maternal Fetal Medicine (SMFM) Meeting
2026-01-13 ET
Natera Announces Next Breakthrough in MRD-Based Risk Stratification, Leveraging Multi-Modal AI Modeling
2026-01-12 ET
Natera to Scale AI Foundation Models in Precision Medicine with NVIDIA
2026-01-11 ET
Natera Announces Strong Preliminary Fourth Quarter and 2025 Financial Results Driven by Record Signatera™ Growth
2026-01-05 ET
Natera Presents Updated Analyses From ALTAIR Clinical Trial at ASCO GI
2026-01-05 ET
Natera Launches 21-Gene Fetal Focus™ Single-Gene NIPT, Powered By Ultra-Sensitive LinkedSNP™ Technology
2025-12-22 ET
Natera to Participate in the 44th Annual J.P. Morgan Healthcare Conference
2025-12-18 ET
Natera Announces Publication of Signatera™ Analysis from Randomized, Phase III CALGB (Alliance)/SWOG 80702 Study in Colorectal Cancer
2025-12-16 ET
I-SPY 2 Publication in Nature Communications Shows Signatera™ Can Predict Treatment Response and Recurrence Risk in Early-Stage Breast Cancer
2025-12-12 ET
Natera and MEDSIR to Collaborate on the MiRaDoR Trial in Breast Cancer
2025-12-10 ET
Phase III PALLAS Study Shows Signatera™ MRD Testing Provides Powerful Post‑Surgical Prognostic Information in Patients with High and Intermediate Risk HR+/HER2‑ Breast Cancer
2025-12-09 ET
Natera Highlights New Findings in Lymphoma at the ASH Annual Meeting
2025-12-05 ET
Natera Acquires Foresight Diagnostics
2025-12-03 ET
New Signatera™ Data in Lymphoma and Multiple Myeloma to be Presented at the 2025 American Society of Hematology Annual Meeting
2025-12-02 ET
Natera to Present 12 Datasets Including >50,000 Patients Featuring Signatera™ at the San Antonio Breast Cancer Symposium
2025-11-19 ET
Employees Volunteer Over 1,500 Hours During Natera’s Annual Volunteer Month
2025-11-12 ET
Natera Integrates with Flatiron Health’s OncoEMR® Platform
2025-11-06 21:05 ET
Natera Reports Third Quarter 2025 Financial Results
2025-10-31 ET
Natera Announces Expansion to 20 Genes for its Fetal Focus™ Single-Gene NIPT
2025-10-30 ET
Natera to Report its Third Quarter Results on November 6, 2025
2025-10-28 ET
Natera Reports Strong Advanced Adenoma Data from Prospective PROCEED-CRC Trial, Demonstrating 22.5% Sensitivity and 91.5% Specificity
2025-10-20 ET
Successful IMvigor011 Trial Achieves 41% Improvement in Overall Survival for Bladder Cancer Patients
2025-10-16 ET
Natera Named to Fast Company’s Next Big Things in Tech List
2025-10-13 ET
Natera to Host Investor Call on October 23, 2025 to Discuss ESMO Findings
2025-10-12 ET
Natera to Present 14 Studies at ESMO, Including IMvigor011 Oral Presentation in Presidential Symposium
2025-10-01 ET
Enrollment Tops 1,600 in Natera’s EXPAND Trial of Single Gene NIPT
2025-09-30 ET
Natera Announces Publication of Signatera™ Validation Study in Testicular Cancer
2025-09-29 ET
Signatera™ Surveillance Testing Identified 100% of Uterine Cancer Recurrences in Advance of Imaging, New Study Shows
2025-08-29 ET
Natera Provides Update on Patent Litigation with NeoGenomics
2025-08-28 ET
Signatera™ Test Selected for NRG-Sponsored Phase III ARCHER Trial in Bladder Cancer
2025-08-25 ET
Natera to Present Signatera™ Data at the IASLC World Conference on Lung Cancer
2025-08-22 ET
Natera Technology Featured in 300+ Peer-Reviewed Publications, Underscoring Scientific Leadership in Precision Medicine
2025-08-22 ET
Natera Launches Proprietary AI Foundation Models to Accelerate Diagnostic and Therapeutic Innovation
2025-08-18 ET
IMvigor011 Bladder Cancer Trial Achieves Positive Results, with Signatera™ Strongly Predicting Adjuvant Immunotherapy Benefit
2025-08-07 ET
Natera Reports Second Quarter 2025 Financial Results
2025-08-07 ET
Natera Launches Fetal Focus™: A Noninvasive Prenatal Test for Inherited Conditions
2025-08-01 ET
Natera Highlights Latest Prospera™ Data at WTC 2025; 16 Abstracts Including Five Oral Presentations
2025-07-31 ET
Natera to Report Its Second Quarter Results on August 7, 2025
2025-07-29 ET
Natera Announces Launch of ABCSG 61 (“TEODOR”), a Randomized Controlled Trial of Signatera™ in Early-Stage Breast Cancer
2025-07-24 ET
PEDAL Study Successful, Shows Monitoring with Prospera™ Kidney Provides Accurate Prognosis of Long-Term Clinical Outcomes Following Rejection; Now Published in AJT
2025-07-07 ET
Natera Presents Data at ESMO GI on its Tissue-Free Latitude™ MRD* Assay, Demonstrating Excellent Overall Performance in Colorectal Cancer
2025-07-01 ET
Natera to Present Clinical and Economic Utility of Signatera at ESMO GI, Highlights Innovations in MRD
2025-06-04 ET
Natera Announces Medicare Coverage for Signatera™ Genome
2025-06-02 ET
SignateraTM Genome Clinical Performance Highlighted at ASCO 2025
2025-05-22 ET
Natera to Present over 25 Signatera™ Studies at 2025 ASCO Annual Meeting
2025-05-08 ET
Natera Reports First Quarter 2025 Financial Results
2025-05-08 ET
Signatera Data From I-SPY 2 Trial to Be Presented at ESMO Breast Annual Congress
2025-05-07 ET
Prospera™ Heart Test with DQS Outperforms dd-cfDNA Percentage in Detecting Allograft Rejection, New AJT Publication Shows
2025-05-05 ET
Largest Sarcoma Study to Date with ctDNA Analysis Demonstrates Excellent Performance for Signatera
2025-05-01 ET
Notice to Shareholders of Natera, Inc. (NTRA) Regarding Dismissal of Putative Investor Class Action
2025-05-01 ET
Natera to Report its First Quarter Results on May 8, 2025
2025-04-29 ET
Prospective DEFINE-HT Study Demonstrates that Prospera™ Heart is Predictive of Clinical Outcomes and Outperforms Biopsy in Predicting Graft Dysfunction
2025-04-24 ET
Natera Announces Broad Clinical Launch of Ultra-Sensitive Signatera™ Genome MRD Test
2025-04-22 ET
Natera To Present Data from 8 Studies at 2025 AACR Annual Meeting
2025-03-25 ET
DEFINE-HT Selected for Late-Breaking Oral Presentation at ISHLT Annual Meeting
2025-03-10 ET
Natera Announces Enrollment of First Patients in the HEROES Clinical Trial in Metastatic HER2+ Breast Cancer
2025-03-04 ET
Natera Expands Intellectual Property Portfolio With New Patents in Tumor-Informed MRD
2025-02-27 ET
Natera Reports Fourth Quarter and Full Year 2024 Financial Results
2025-02-25 ET
Natera Announces Medicare Coverage of Signatera™ for Surveillance in Lung Cancer
2025-02-18 ET
Natera to Report its Fourth Quarter and Full Year Results on February 27, 2025
2025-02-10 ET
NCCN Strengthens Guidance on ctDNA in Colon Cancer, Rectal Cancer, and Merkel Cell Carcinoma
2025-02-03 ET
Natera Announces National Commercial Coverage for its Fetal RhD NIPT
2025-01-25 ET
Natera Announces Successful Readout of Randomized, Phase III CALGB (Alliance) / SWOG 80702 Clinical Trial in Colorectal Cancer
2025-01-21 ET
Natera to Present New Data at the 2025 ASCO GI Symposium
2025-01-17 ET
Natera CEO Steve Chapman Recognized as a 2024 Top Healthcare Technology CEO and BioTechnology Innovator of the Year
2025-01-15 ET
Natera Announces Innovation Roadmap, with Advancements in MRD and Early Cancer Detection
2025-01-12 ET
Natera Announces Preliminary Fourth Quarter and Full-Year Results for 2024
2025-01-07 ET
Natera to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
2024-12-17 ET
Court Grants Natera’s Request to Include Additional Patent in its Lawsuit Against NeoGenomics
2024-12-12 ET
Natera Announces Enrollment of First Patients in SAGITTARIUS: a Randomized, Phase III Clinical Trial in Colon Cancer
2024-12-09 ET
Natera and MyOme Announce Launch of iPRS™ for Breast Cancer Risk Assessment
2024-12-02 ET
Clinical Validation Study on Natera’s Fetal RhD NIPT Published in Obstetrics & Gynecology
2024-11-27 ET
Natera Announces Medicare Coverage for Prospera™ in Single Lung Transplant Recipients
2024-11-25 ET
Natera to Present New SignateraTM Data in Multiple Abstracts at the San Antonio Breast Cancer Symposium
2024-11-25 ET
Federal Court Jury Issues Unanimous Verdict that Natera Engaged in False Advertising and Unfair Competition in Deliberate Attempt to Damage Guardant Health's Colorectal Cancer Test, Guardant Reveal™
2024-11-25 ET
Natera Issues Statement on Guardant Health Litigation
2024-11-25 ET
Natera Co-Founder and Executive Chairman Matthew Rabinowitz Named 2024 R&D Leader of the Year
2024-11-21 ET
Natera Announces Publication of over 100 Peer-Reviewed Papers on SignateraTM
2024-11-12 21:05 ET
Natera Reports Third Quarter 2024 Financial Results
2024-11-12 12:00 ET
Natera Announces Completion of Signatera™ Analysis from the CALGB (Alliance)/SWOG 80702 Randomized, Phase III Clinical Trial in Colorectal Cancer
2024-11-08 14:00 ET
Natera to Participate in Upcoming Investor Conferences
2024-11-01 13:00 ET
Natera to Report its Third Quarter 2024 Results on November 12, 2024
2024-10-22 13:00 ET
Natera to Present New Renasight Data at ASN Kidney Week 2024
2024-09-23 20:06 ET
Court Orders Permanent Injunction Against NeoGenomics' Accused RaDaR Assay, as Case Enters New Phase
2024-09-16 09:17 ET
 Natera Announces Three New Signatera Publications; Includes Groundbreaking Overall Survival Data Published in Nature Medicine and also Released at ESMO
2024-09-14 18:16 ET
First of its Kind Colorectal Cancer Data from Prospective GALAXY Study Released at ESMO; Demonstrates Signatera's Ability to Predict Overall Survival
2024-09-09 00:22 ET
Natera to Present New Signatera™ Colorectal Cancer Data at ESMO Showing 10X Advantage in Overall Survival
2024-08-28 13:00 ET
Natera to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
2024-08-08 20:05 ET
Natera Reports Second Quarter 2024 Financial Results
2024-08-06 13:00 ET
Natera to Participate in the Canaccord Genuity 44th Annual Growth Conference
2024-07-30 20:05 ET
Natera to Report its Second Quarter 2024 Results on August 8, 2024
2024-07-26 12:00 ET
New MultiCenter Prospective Study Demonstrates Signatera’s Clinical Utility in Merkel Cell Carcinoma
2024-07-03 11:00 ET
Natera to Present at the 28th International Conference on Prenatal Diagnosis and Therapy
2024-06-27 11:00 ET
Natera Announces DECIPHER: A Phase II, Single-Arm Adjuvant Trial in Gastroesophageal Cancer
2024-06-17 11:00 ET
Natera Launches Differentiated New Feature for Prospera™ Heart Test, Enhancing Detection of Rejection for Transplant Patients
2024-06-03 12:00 ET
Natera to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
2024-05-30 12:00 ET
Natera Presents Latest in Transplant Innovation Data Across Multiple Organs at ATC 2024
2024-05-23 20:05 ET
Natera to Present at the 2024 Leerink Partners Healthcare Crossroads Conference
2024-05-23 11:30 ET
Natera Announces New MRD Data in Multiple Tumor Types, to be Presented at ASCO Annual Meeting
2024-05-09 20:05 ET
Natera Reports First Quarter 2024 Financial Results
2024-05-03 12:00 ET
New Natera Publication Bolsters Evidence for Extended Surveillance with Signatera™ in Breast Cancer
2024-05-01 20:05 ET
Natera to Report its First Quarter 2024 Results on May 9
2024-05-01 11:00 ET
Natera Launches Fetal RhD NIPT Supporting Ob/Gyn Physicians and Patients During RhIg Shortage
2024-04-22 12:00 ET
Natera Announces Significant Milestone with 200+ Peer-Reviewed Publications
2024-04-11 12:00 ET
Natera Announces Publication of Largest Prospective dd-cfDNA Study in Kidney Transplantation
2024-04-08 12:00 ET
Natera Announces New Data From Two Studies Extending the Clinical Validation of Its Prospera™ Heart dd-cfDNA Test for Heart Transplant Recipients
2024-04-05 11:00 ET
Natera Announces Positive Surveillance Analysis from the Randomized Phase III IMvigor011 Trial in Muscle-Invasive Bladder Cancer
2024-04-01 12:00 ET
Natera and Alliance for Clinical Trials in Oncology Announce Activation of Alliance A032103 (MODERN): A Randomized, Phase II/III Adjuvant Trial in Urothelial Cancer
2024-03-18 11:00 ET
Natera Announces Phase III Randomized CIRCULATE Trial in France, Evaluating Signatera™ in Stage II Colorectal Cancer
2024-03-14 12:00 ET
New KDIGO Guideline Supports Genetic Testing for the Majority of CKD Patients to Establish Cause of Disease
2024-03-12 12:00 ET
Natera to Present New Data at the 2024 SGO Annual Meeting on Women’s Cancer, Following Recent Medicare Coverage Decisions in Ovarian and Breast Cancers
2024-03-07 13:00 ET
Natera Announces Commercial Coverage for Prospera™ Kidney and Prospera Heart™ from a Top BCBS Plan
2024-02-29 13:00 ET
Natera to Participate in March Investor Conferences
2024-02-28 21:05 ET
Natera Reports Fourth Quarter and Full Year 2023 Financial Results
2024-02-27 13:00 ET
Natera Announces Next Phase of CareDx Patent Infringement Litigation Seeking Royalty For All Ongoing And Future AlloSure Tests
2024-02-26 12:00 ET
Medicare Extends Coverage of Natera’s Signatera™ MRD Test to Ovarian Cancer and Neoadjuvant Breast Cancer
2024-02-20 13:00 ET
Natera Announces Fourth Quarter and Fiscal 2023 Earnings Conference Call
2024-02-05 13:00 ET
New Study Validates Signatera™ in Endometrial Cancer
2024-01-30 12:00 ET
New Publication Demonstrates Signatera’s Ability to Risk Stratify and Detect Recurrence Early in Resected Stage I-II Lung Cancer
2024-01-29 12:00 ET
Jury Rules in Favor of Natera in Patent Infringement Lawsuit Against CareDx; Awards $96.3 Million in Damages to Natera in Lost Profits and Past Royalties
2024-01-25 12:00 ET
Nature Medicine Publishes Two Studies Highlighting Signatera’s Clinical Utility in Patients with Gastrointestinal Malignancies
2024-01-18 13:00 ET
Natera to Present New Data from the CIRCULATE-Japan and BESPOKE CRC Studies at ASCO GI 2024 Supporting Signatera’s Clinical Utility in CRC
2024-01-16 22:17 ET
Natera Provides Update on Ravgen Trial
2024-01-09 12:00 ET
Natera Announces Preliminary Fourth Quarter and Full Year 2023 Revenues
2023-12-29 13:00 ET
Natera to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
2023-12-28 04:48 ET
Natera Wins Preliminary Injunction in Patent Infringement Lawsuit Against NeoGenomics’ RaDaR Test
2023-12-21 13:00 ET
Natera Announces New Study Highlighting the Benefits of Signatera’s Unique Method of Quantifying ctDNA
2023-12-11 17:50 ET
Delaware Court Denies CareDx’s Motion for Summary Judgment on Two Natera Patents
2023-12-06 13:30 ET
Natera Presents New Signatera™ MRD Data Across Breast Cancer Treatment Settings at SABCS 2023
2023-11-14 13:00 ET
Natera Announces Real-World Data Collaboration with Merck
2023-11-08 21:05 ET
Natera Reports Third Quarter 2023 Financial Results
2023-11-08 14:10 ET
Natera Announces Randomized, Phase III TREAT ctDNA Trial in Early-Stage Breast Cancer
2023-11-07 13:30 ET
Natera to Participate in November Investor Conferences
2023-11-02 12:30 ET
Natera’s Landmark RenaCARE Study Demonstrates Significant Diagnostic and Clinical Utility of Renasight™ in Chronic Kidney Disease
2023-10-22 17:00 ET
Updated Data from CIRCULATE-Japan Presented at ESMO 2023 Reinforces Signatera’s Prognostic and Predictive Value in Analysis of 2,500+ Colorectal Cancer Patients
2023-10-20 13:00 ET
Natera to Report its Third Quarter 2023 Results on November 8
2023-10-19 13:00 ET
Natera Recognized on U.S. News & World Report’s 2024 Best Companies to Work for in Healthcare Ranking
2023-10-16 13:00 ET
Natera to Present New Signatera™ MRD Data at ESMO 2023, Featuring Large, Updated Analysis from CIRCULATE-Japan Study
2023-10-04 13:00 ET
New MRD Publication in Unresectable Stage I-III Lung Cancer Demonstrates Signatera’s Ability to Risk Stratify and Detect Progression Early
2023-10-03 20:43 ET
Supreme Court Denies CareDx Request for Appeal in Patent Case with Natera
2023-10-02 13:00 ET
Natera Submits First PMA Module to the FDA for Signatera™
2023-09-18 13:00 ET
Natera Announces Senior Leadership Appointments
2023-09-14 13:00 ET
Natera Announces Expanded I-SPY 2 Collaboration to Evaluate Signatera™ for Breast Cancer Patients in the Neoadjuvant Setting
2023-09-07 04:09 ET
Natera Announces Pricing of $250 Million Follow-On Offering
2023-09-06 20:24 ET
Natera Launches Proposed Follow-On Offering
2023-09-01 13:00 ET
Natera to Participate in Upcoming Investor Conferences
2023-08-16 13:00 ET
Natera’s Prospera™ Lung Transplant Assessment Test Granted Medicare Coverage
2023-08-03 20:05 ET
Natera Reports Second Quarter 2023 Financial Results
2023-08-02 20:05 ET
Natera to Participate in Canaccord Genuity 43rd Annual Growth Conference
2023-07-31 17:39 ET
Natera Files Patent Infringement Suit Against NeoGenomics
2023-07-28 13:00 ET
Natera Announces Completion of Enrollment to the Randomized, Phase III ALTAIR Trial of Signatera™ in Colorectal Cancer
2023-07-27 12:00 ET
Natera to Report its Second Quarter 2023 Results on August 3rd
2023-07-17 20:47 ET
Court Issues Favorable Ruling for Natera in False Advertising Trial Against CareDx; Eliminates all Damages
2023-06-06 12:30 ET
Natera to Participate in Goldman Sachs 44th Annual Global Healthcare Conference
2023-06-04 23:08 ET
Natera Announces Data from the ProActive Study that Supports Prospera™ Kidney as an Early Indicator of Transplant Rejection
2023-05-30 12:30 ET
New Natera Data to be Presented at the 2023 ASCO Annual Meeting in 13 Studies Across Multiple Cancer Types
2023-05-15 17:48 ET
Jury Rules in Favor of Natera, Finding all Asserted Patents Valid and Infringed by ArcherDX/Invitae; Awards $19.35 Million in Past Damages for Royalties and Lost Profits
2023-05-09 20:05 ET
Natera Reports First Quarter 2023 Financial Results
2023-05-08 12:00 ET
Natera Announces New Publication from I-SPY2 Trial Reinforcing Clinical Utility of Signatera™ for Breast Cancer Patients in the Neoadjuvant Setting
2023-05-02 12:00 ET
Natera Announces First Quarter 2023 Earnings Conference Call
2023-04-14 12:00 ET
Natera Announces New Signatera™ MRD Data at 2023 AACR Annual Meeting
2023-03-22 12:00 ET
New Publication Demonstrates Utility of Natera’s Signatera™ Test in Melanoma
2023-03-02 12:00 ET
Natera Announces Commercial Payor Coverage for Signatera™
2023-02-28 21:05 ET
Natera Reports Fourth Quarter and Full Year 2022 Financial Results
2023-02-24 13:00 ET
Natera to Participate in Upcoming Investor Conferences
2023-02-23 13:05 ET
Natera Appoints Ruth E. Williams-Brinkley to its Board of Directors
2023-02-21 13:00 ET
Natera Announces Fourth Quarter and Fiscal 2022 Earnings Conference Call
2023-02-16 13:00 ET
Medicare Extends Coverage of Natera’s Signatera™ MRD Test to Breast Cancer
2023-02-02 13:01 ET
New Paper Highlights Clinical Utility of Natera’s Renasight™ Test in the Management of Kidney Disease
2023-01-19 13:02 ET
New Signatera™ MRD Data in Gastrointestinal Cancers to be Presented at the ASCO GI Symposium 2023
2023-01-17 13:01 ET
Natera Announces Publication of Prospective, Multi-Site CIRCULATE Study in Nature Medicine Demonstrating Signatera’s Ability to Predict Chemotherapy Benefit in Colorectal Cancer
2023-01-03 21:05 ET
Natera to Webcast Live Presentation at the 41st Annual J.P. Morgan Healthcare Conference
2022-12-22 00:23 ET
Natera Supports Updated ISHLT Guidelines for the Care of Heart Transplant Patients
2022-12-09 13:33 ET
Natera Announces Publication of Multi-Center Study Validating Signatera's Ability to Predict Recurrence in Esophageal and Gastric Cancers
2022-12-07 13:33 ET
Natera to Present New Signatera™ and Empower™ Data at the 2022 Annual San Antonio Breast Cancer Symposium
2022-12-06 10:31 ET
Natera Announces Publication of Clinical Experience Study with 18,984 Twin Pregnancies Supporting Excellent Performance of Panorama™ NIPT
2022-11-23 13:33 ET
Natera to Participate in the Piper Sandler 34th Annual Healthcare Conference
2022-11-21 13:33 ET
New Published Study Further Demonstrates the Ability of Natera's mPCR Technology to Monitor Immunotherapy Response in Metastatic Uveal Melanoma Patients
2022-11-16 04:01 ET
Natera Announces Pricing of Follow-On Offering
2022-11-15 21:30 ET
Natera Launches Proposed Follow-On Offering
2022-11-08 21:05 ET
Natera Reports Third Quarter 2022 Financial Results
2022-11-02 12:33 ET
Natera Awarded National MRD Testing Contract by the U.S. Department of Veterans Affairs
2022-11-01 15:00 ET
Natera to Participate in Credit Suisse 31st Annual Healthcare Conference
2022-11-01 12:30 ET
Natera to Report its Third Quarter 2022 Results on November 8th
2022-10-06 12:33 ET
New Publication Validates Performance of Natera's Signatera™ MRD Test in Ovarian Cancer
2022-10-04 12:33 ET
Trifecta Study Demonstrates Prospera™ Kidney dd-cfDNA Test Outperforms DSA in Predicting Antibody Mediated Rejection
2022-09-29 12:33 ET
Natera Announces 2025 ESG Goals with Publication of 2021 Report
2022-09-12 13:27 ET
Natera Presents New Colorectal and Breast Cancer Data at ESMO 2022, Highlighting Signatera's Ability to Inform Treatment Decisions in the Adjuvant and Neoadjuvant Settings
2022-09-06 17:32 ET
Natera to Participate in Upcoming Investor Conferences
2022-08-25 12:35 ET
Natera Earns Great Place to Work Certification™ for Second Consecutive Year
2022-08-11 11:32 ET
Natera Announces Enrollment Completion for RenaCARE Study
2022-08-10 20:15 ET
Natera Announces Q-Sub Filing with FDA for its Panorama® NIPT
2022-08-04 20:05 ET
Natera Reports Second Quarter 2022 Financial Results
2022-08-01 17:13 ET
Natera Announces Second Quarter 2022 Earnings Conference Call
2022-07-18 17:35 ET
Federal Circuit Rules in Favor of Natera, Upholding Invalidation of CareDx Patents
2022-07-18 12:33 ET
Medicare Extends Coverage of Natera's Signatera™ MRD Test to Muscle Invasive Bladder Cancer
2022-07-14 11:33 ET
Natera Selected for UnitedHealthcare's Preferred Laboratory Network
2022-06-29 15:56 ET
Trifecta Study Establishes New Validation Standard for dd-cfDNA in Kidney Transplant Rejection With Largest Prospective, Multisite, Fully Biopsy-Matched Study
2022-06-09 21:51 ET
Securities Litigation Partner Lubna M. Faruqi Encourages Investors Who Suffered Losses Exceeding $100,000 In Natera To Contact Him Directly To Discuss Their Options
2022-06-08 11:33 ET
Natera Showcases Leadership in Transplantation at ATC 2022 with New Data on its Prospera and Renasight Tests
2022-05-31 12:33 ET
Natera to Present New Signatera™ Clinical Data Across Multiple Cancer Types at the 2022 ASCO Annual Meeting
2022-05-24 12:03 ET
Natera Appoints Minetta Liu, M.D. as Chief Medical Officer of Oncology
2022-05-16 11:30 ET
Matthew Rabinowitz, Natera Co-Founder and Executive Chairman of the Board, Makes Additional Investment in Natera
2022-05-05 20:05 ET
Natera Reports First Quarter 2022 Financial Results
2022-05-02 12:03 ET
Natera Announces First Quarter 2022 Earnings Conference Call
2022-04-26 11:33 ET
Natera Announces Definitive Study to Evaluate the Clinical Utility of Renasight in the Diagnosis and Management of Chronic Kidney Disease (CKD)
2022-04-19 11:33 ET
Large Real-World Study with Renasight Genetic Test Highlights High Diagnostic Yield for Patients with Chronic Kidney Disease
2022-04-15 21:44 ET
Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Natera To Contact Him Directly To Discuss Their Options
2022-04-13 11:33 ET
Multi-Site Clinical Validation of Prospera Heart Test Demonstrates Outstanding Performance in Assessing Heart Transplant Rejection
2022-04-11 11:33 ET
Natera to Present Data from the BEATRICE and I-SPY2 Trials in Early-Stage TNBC and HR+/HER2- Breast Cancer at the 2022 AACR Annual Meeting
2022-04-07 11:33 ET
Natera Publishes VALID Study Results for Prospera Lung dd-cfDNA Transplant Rejection Assessment Test
2022-04-06 11:33 ET
Natera Adds to Organ Health Medical Affairs Leadership Team
2022-04-01 11:33 ET
Natera Announces Publication Highlighting Importance of Testing Total cfDNA when Monitoring Kidney Transplant Patients with COVID-19 Infection
2022-03-28 11:33 ET
Natera Listed as One of World's Most Innovative Health Companies by Fast Company
2022-03-23 10:00 ET
UPDATE -- CareDx Wins $44.9M in Damages in False Advertising Trial Against Natera; Natera Intentionally Deceived Transplant Community
2022-03-22 11:33 ET
New Data in Simultaneous Pancreas-Kidney Transplantation Further Demonstrates the Value of Prospera dd-cfDNA Technology
2022-03-21 11:33 ET
Natera Announces Updated Signatera™ MRD Data from CIRCULATE-Japan Presented in Plenary Talk at the Society of Surgical Oncology Conference, and Activation of CIRCULATE-US Trial
2022-03-16 15:04 ET
Roelof Botha, Lead Independent Director of Natera Board, Makes $5 Million Investment in Natera
2022-03-15 05:14 ET
Jury Finds CareDx and Natera Engaged in False Advertising
2022-03-15 00:06 ET
CareDx Wins $44.9M in Damages in False Advertising Trial Against Natera; Natera Intentionally Deceived Transplant Community
2022-03-14 13:35 ET
NTRA Alert: Monsey Firm of Wohl & Fruchter LLP Investigating Natera, Inc.
2022-03-14 11:00 ET
Natera Executives and Board to Take Pay in Stock Instead of Cash
2022-03-11 12:30 ET
Natera Achieves Milestone of Enrolling First 1,000 Patients in its BESPOKE CRC Study
2022-03-09 23:42 ET
Natera to Host Special Investor Call in Response to Misleading Short Seller Report
2022-03-09 19:33 ET
NATERA RESPONDS TO MISLEADING SHORT SELLER REPORT
2022-02-24 21:05 ET
Natera Reports Fourth Quarter and Full Year 2021 Financial Results
2022-02-17 22:48 ET
Natera Announces Fourth Quarter and Fiscal 2021 Earnings Conference Call
2022-02-17 13:35 ET
Natera Announces Results of Large, Multi-Center Clinical Experience Study Showing Excellent Positive Predictive Value of the Prospera™ Kidney Test
2022-02-15 13:35 ET
Natera to Participate in Upcoming Investor Conferences
2022-01-22 19:22 ET
Landmark CIRCULATE-Japan Study Shows Natera's Signatera™ MRD Test is Predictive of Chemotherapy Benefit in Colorectal Cancer
2022-01-20 13:33 ET
Landmark SMART Study Demonstrates High Accuracy of Natera’s Panorama® NIPT for 22q11.2 Deletion Screening
2022-01-19 13:33 ET
Natera to Present Latest Signatera™ MRD Data in Colorectal and Pancreatic Cancers at the ASCO GI Symposium 2022, and Host Special Investor Call
2022-01-17 17:07 ET
FeganScott Announces Investigation into Prenatal Testing Options Revealing Flawed Genetic Results
2022-01-06 13:33 ET
Natera Announces Expansion Into Early Cancer Detection and Screening
2022-01-04 13:33 ET
Natera to Webcast Live Presentation at the 40th Annual J.P. Morgan Healthcare Conference
2022-01-03 13:33 ET
Signatera™ Wins Fierce Life Sciences Innovation Award
2021-12-09 14:03 ET
Natera Presents Latest Signatera™ MRD Data in Breast Cancer at SABCS 2021
2021-11-19 14:00 ET
Natera's Panorama SMART Study Results Accepted for Publication by the American Journal of Obstetrics and Gynecology (AJOG)
2021-11-11 16:52 ET
Medicare Publishes Final Local Coverage Determination for Pan-Cancer Immunotherapy Monitoring with Natera's Signatera™ MRD Test
2021-11-04 20:05 ET
Natera Reports Third Quarter 2021 Financial Results
2021-11-03 12:33 ET
Natera Validates Prospera™ With Quantification in Multi-Site, Prospective Trifecta Study
2021-10-28 12:33 ET
Natera Announces Third Quarter 2021 Earnings Conference Call
2021-10-18 12:33 ET
Natera Expands Organ Health Business With Commercial Launch of the Prospera™ Lung Transplant Assessment Test
2021-10-11 12:33 ET
Natera Announces New Publication Validating Signatera® Velocity Metric to Improve Cancer Management
2021-10-06 12:33 ET
Natera Announces Completion of the Largest Prospective Validation Study of a Commercial Cell-Free DNA Test in Lung Transplantation
2021-09-29 04:30 ET
Court Rules in Natera's Favor Invalidating All of CareDx's Asserted Patents
2021-09-17 12:33 ET
Natera Releases New Clinical Data at ESMO 2021 in Gastroesophageal Cancer and Uveal Melanoma
2021-09-09 12:33 ET
Natera Launches Prospera™ Kidney with Quantification to Further Improve Test Performance, Demonstrating Commitment to Innovation in Transplantation
2021-09-07 10:03 ET
Natera's Signatera® Test Selected for NRG Oncology's Landmark CIRCULATE-US Study of MRD-Guided Treatment in Stage II-III Colon Cancer
2021-08-31 12:30 ET
Natera Announces the Validation and Launch of the Prospera™ Heart Transplant Assessment Test
2021-08-10 13:03 ET
Natera to Participate in Upcoming Investor Conferences
2021-08-05 20:05 ET
Natera Reports Second Quarter 2021 Financial Results
2021-08-04 13:03 ET
Natera Announces Use of Signatera® as a Companion Diagnostic in GSK's Phase III ZEST Trial for Niraparib in Early-Stage Breast Cancer
2021-07-29 13:03 ET
Natera Announces Second Quarter 2021 Earnings Conference Call
2021-07-28 13:03 ET
New Study Validates the Signatera® MRD Test and Demonstrates its Clinical Utility in Early-Stage Esophageal Cancer
2021-07-22 13:00 ET
New Publication Shows 96% Overall Survival Among Metastatic Colorectal Cancer Patients Who Test MRD-Negative with Signatera® After Surgery
2021-07-22 04:25 ET
Natera Announces Pricing of Follow-On Offering
2021-07-20 21:06 ET
Natera Launches Proposed Follow-On Offering
2021-07-19 12:46 ET
Natera Reports Preliminary Second Quarter 2021 Results
2021-07-02 15:00 ET
New Results From the Landmark Prospective CIRCULATE Trial Expand Clinical Utility of the Signatera® MRD Test in Colorectal Cancer
2021-06-24 13:03 ET
Natera and BGI Genomics Announce Commercial Launch of the BGI/Natera Signatera Assay in China
2021-06-18 13:03 ET
Natera Awarded Advanced Diagnostic Laboratory Test (ADLT) Status for its Signatera® MRD Test From CMS
2021-06-16 15:20 ET
Nature Journal Publishes Prospective, Randomized Study Validating Signatera® for Prediction of Immunotherapy Benefit
2021-06-08 11:03 ET
Foundation Medicine Launches FoundationOne®Tracker ctDNA Monitoring Assay for Research Use in Partnership with Natera
2021-06-08 11:00 ET
Foundation Medicine Launches FoundationOne®Tracker ctDNA Monitoring Assay for Research Use in Partnership with Natera
2021-06-04 13:03 ET
Natera Announces New Prospera™ Data at the ATC 2021 Virtual Connect Conference
2021-05-28 20:52 ET
Natera Responds to Meritless Lawsuit and Files False Advertising Claim Against Guardant for Misleading Oncologists
2021-05-26 13:03 ET
New Signatera™ Data in Multiple Myeloma, Colorectal Cancer and Ovarian Cancer Highlights Clinical Utility of MRD in Real-World Settings
2021-05-20 13:03 ET
Natera to Present Clinical Data from Largest Prospective MRD-Guided Trial in Colorectal Cancer at the 2021 ASCO Annual Meeting
2021-05-06 20:05 ET
Natera Reports First Quarter 2021 Financial Results
2021-05-03 13:03 ET
Natera to Present New Colorectal Cancer and Multiple Myeloma Data at the 2021 Annual ASCO Meeting
2021-04-29 13:03 ET
Natera Announces First Quarter 2021 Earnings Conference Call
2021-04-22 15:20 ET
Prospera™ Transplant Assessment Test: Path Established to Expand Future Coverage to Multiple Organs
2021-04-07 13:56 ET
Natera Implements First Wave of Panorama® AI Improvements With Immediate Impact on Patient Experience and COGS
2021-03-31 13:07 ET
Natera and Tesis Labs Announce Strategic Collaboration on Prenatal Genetic Testing
2021-03-24 13:03 ET
FDA Grants Two New Breakthrough Device Designations for Natera's Signatera™ MRD Test
2021-03-10 14:03 ET
Natera and Genentech Initiate Phase III Trial Using Signatera™ as a Companion Diagnostic for Atezolizumab in Early-Stage Muscle-Invasive Bladder Cancer
2021-02-25 21:05 ET
Natera Reports Fourth Quarter and Year 2020 Financial Results
2021-02-23 14:03 ET
Natera to Participate in the Cowen 41st Annual Health Care Conference
2021-02-18 14:03 ET
Natera Announces Fourth Quarter and Fiscal 2020 Earnings Conference Call
2021-02-11 14:03 ET
Natera to Participate in Upcoming Investor Conferences
2021-02-03 14:03 ET
Panorama® SMART Study Confirms Market-Leading Performance in Largest Prospective NIPT Trial to Date
2021-02-01 14:03 ET
SMART Study Finds 22q11.2 Microdeletion Prevalence Much Higher than Expected
2021-01-20 20:04 ET
Natera Files Patent Infringement Suit Against Inivata
2021-01-14 15:35 ET
New Data at the 2021 ASTS Winter Symposium to Showcase Benefit of Serial Prospera™ Testing
2021-01-12 14:03 ET
Natera to Present New Colorectal Cancer Data at the 2021 ASCO GI Symposium
2021-01-05 14:03 ET
Natera to Webcast Live Presentation at the 39th Annual J.P. Morgan Healthcare Conference
2020-12-18 14:03 ET
U.S. Patent Office Upholds Validity of Natera's Early Priority Date '592 cfDNA Patent
2020-12-09 14:03 ET
New Signatera™ Data to be Presented at the 2020 ESMO IO Congress from the Phase III IMvigor010 Trial
2020-12-08 14:03 ET
Natera to Present New Immunotherapy Monitoring Data at SABCS 2020
2020-12-03 14:03 ET
Second Largest Commercial Insurer Covers Non-Invasive Prenatal Testing for All Pregnancies
2020-12-01 15:32 ET
Largest U.S. Health Plan Now Covers Non-Invasive Prenatal Testing (NIPT) for all Pregnancies
2020-11-30 14:03 ET
New Publication from I-SPY 2 Trial Highlights Signatera's Ability to Predict Treatment Outcomes in Neoadjuvant Breast Cancer Patients
2020-11-19 14:03 ET
Natera Appoints Dr. Monica Bertagnolli to its Board of Directors
2020-11-12 14:03 ET
Natera to Present at the Canaccord Genuity Virtual MedTech & Diagnostics Forum
2020-11-10 14:03 ET
Natera Presents New Data at the 2020 SITC Annual Meeting Highlighting Applications of Personalized ctDNA Testing in Immunotherapy Treatment Monitoring
2020-11-05 21:05 ET
Natera Reports Third Quarter 2020 Financial Results
2020-10-30 13:03 ET
International Society for Prenatal Diagnosis Recommends cfDNA Screening in Twin Pregnancies
2020-10-29 17:05 ET
Natera Announces Third Quarter 2020 Earnings Conference Call
2020-10-29 13:03 ET
NIPT for Average Risk Now Covered for 139 Million Commercial Lives
2020-10-21 13:03 ET
Natera to Present New Data at ASN Kidney Week 2020 Showing Clinical Differentiation of the Prospera™ Test
2020-10-08 13:03 ET
Natera's Panorama® NIPT Receives Average Risk Coverage for an Additional 24 Million Lives
2020-10-05 13:13 ET
Natera Teams Up with the George Lopez Foundation on the #GLFTrickShot Kidney Disease Awareness Challenge
2020-10-05 13:03 ET
Court Rejects ArcherDX's Motion to Dismiss Natera's Patent Infringement Case
2020-10-02 13:03 ET
Natera Announces Prospective Randomized Clinical Trial to Evaluate Palbociclib in Early Stage Breast Cancer Patients Who Test Positive with Signatera™
2020-09-24 19:49 ET
Medicare Issues Draft Local Coverage Determination for Signatera™ in Immunotherapy Response Monitoring
2020-09-18 13:03 ET
Natera to Present New Gastrointestinal Cancer Data at the ESMO Annual Meeting
2020-09-14 13:03 ET
Natera Launches Initiative to Transform the Management of Cancer Patients in Organ Transplantation
2020-09-11 13:03 ET
Natera's Signatera™ MRD Test Receives a Final Coverage Decision from Noridian in Colorectal Cancer
2020-09-11 04:53 ET
Natera Announces Pricing of Follow-On Offering
2020-09-10 18:41 ET
Natera to Present at the Morgan Stanley 18th Annual Global Healthcare Conference
2020-09-09 21:07 ET
Natera Launches Proposed Follow-On Offering
2020-09-03 14:37 ET
Natera Receives Final Medicare Coverage for its Signatera™ MRD Test in Stage II-III Colorectal Cancer
2020-09-02 22:43 ET
SMART Study Data for Aneuploidy and 22q Unblinded
2020-09-01 13:03 ET
Study Shows Clinical Utility of the Prospera™ Test in Nephrology Practice
2020-08-27 13:03 ET
Natera Announces Collaboration with Massachusetts General Hospital for a Prospective Randomized Clinical Trial in Early Stage Breast Cancer
2020-08-26 13:03 ET
Natera's Signatera™ Test Receives CE Mark
2020-08-18 13:03 ET
Joint Guideline from ACOG and SMFM Supports use of Non-Invasive Prenatal Testing (NIPT) for all Pregnant Women
2020-08-07 13:03 ET
Natera Files Additional Suit Against ArcherDX
2020-08-05 20:05 ET
Natera Reports Second Quarter 2020 Financial Results
2020-08-03 15:20 ET
New Publication in Nature Cancer Demonstrates Signatera's Ability to Evaluate Tumor Response to Immunotherapy
2020-07-29 13:03 ET
Natera Announces Second Quarter 2020 Earnings Conference Call
2020-07-14 13:03 ET
Natera Recognized as a 'Force for Change' by Leading Women Entrepreneurs (LWE)
2020-07-07 13:03 ET
Natera Announces Clinical Data at ESMO GI Supporting Personalized ctDNA Testing for Oligometastatic Colorectal Cancer (CRC) Patients
2020-06-22 13:03 ET
Natera Expands Lab Footprint With State-Of-The-Art Facility in Austin, Texas
2020-06-18 13:05 ET
Natera Announces First Patient Enrollments in Both CIRCULATE-Japan and BESPOKE CRC Trials Using Signatera™ MRD Testing
2020-06-17 16:22 ET
Natera Files Patent Suit Against Progenity, Inc.
2020-06-01 13:07 ET
Natera Launches Quantification Technique to Enhance Prospera™ Test Precision; Initiates PEDAL Study for New Insights
2020-05-26 14:08 ET
Natera Announces New Prospera™ Data at ATC Showcasing Innovation in Cell-Free DNA
2020-05-19 13:03 ET
Natera Announces New Data at ASCO Highlighting Utility of Personalized MRD Monitoring
2020-05-18 13:03 ET
Natera and Illumina Settle Patent Dispute
2020-05-13 13:03 ET
Natera to Present at the UBS Virtual Global Healthcare Conference
2020-05-11 18:40 ET
Prospera™ Receives Positive Medicare Coverage
2020-05-06 20:05 ET
Natera Reports First Quarter 2020 Financial Results
2020-05-04 13:03 ET
Natera Announces Achievement of Key Recruitment Milestones in ProActive Study and Success in Prospera™ Early Access Program
2020-04-29 13:03 ET
Natera Announces First Quarter 2020 Earnings Conference Call
2020-04-15 13:23 ET
Natera Asserts Three New Oncology Patents Against ArcherDX
2020-04-14 04:04 ET
Natera Prices $250 Million Convertible Senior Notes Due 2027
2020-04-13 11:11 ET
Natera to Offer $250 Million Convertible Senior Notes Due 2027
2020-04-13 11:04 ET
Natera Announces Preliminary First Quarter 2020 Financial Results
2020-04-06 13:04 ET
Coverage for Natera's Panorama® Prenatal Test Extended by Greater Than 20 Million Lives
2020-04-02 13:15 ET
New Study Shows Benefit of Using Signatera™ Technology for Personalized Monitoring in Gastrointestinal Cancer
2020-03-19 13:03 ET
Natera Provides Remote Access to Tests Without Requiring Live Office Visits
2020-03-04 14:05 ET
Natera to Showcase Leadership in Cell-Free DNA at CEoT Conference
2020-03-03 14:14 ET
Natera to Participate in Upcoming Investor Conferences
2020-03-03 14:03 ET
Natera Receives Favorable Medicare Reimbursement Pricing for Prospera™
2020-02-26 21:10 ET
Natera Reports Fourth Quarter and Year 2019 Financial Results
2020-02-20 01:57 ET
Natera Announces Fourth Quarter and Fiscal 2019 Earnings Conference Call
2020-02-18 14:20 ET
Natera Files False Advertising Counterclaim Against CareDx
2020-02-11 14:05 ET
Elicio Therapeutics and Natera to Collaborate in Phase I/II Pancreatic Cancer Study of ELI-002
2020-01-27 14:13 ET
Natera Files Suit Against ArcherDX for Patent Infringement
2020-01-15 13:42 ET
National Cancer Center Japan Launches Multi-Center Randomized Trial Using Signatera™ MRD Testing in Stage II-III Colorectal Cancer
2020-01-15 13:42 ET
National Cancer Center Japan Launches Multi-Center Randomized Trial Using Signatera(TM) MRD Testing in Stage II-III Colorectal Cancer
2020-01-13 14:26 ET
Natera Announces New Early Priority Date cfDNA Patent, Files Suit Against CareDx
2020-01-09 14:05 ET
Natera Launches BESPOKE CRC Study to Evaluate Outcomes in 1,000 Signatera(TM) Patients with Stage II-III Colorectal Cancer
2020-01-08 12:35 ET
Natera To Webcast Live Presentation at the 38th Annual J.P. Morgan Healthcare Conference
2020-01-06 13:30 ET
Natera Announces Achievement of $55 Million In Pharma Contracts and Issuance of New Oncology Patents
2019-12-19 16:32 ET
Natera Receives Final Medicare Coverage for Prospera(TM) Organ Transplant Rejection Assessment Test
2019-11-27 13:20 ET
Panorama Publication Demonstrates Utility of Measuring Individual Fetal Fractions in Twin Pregnancies
2019-11-06 21:05 ET
Natera Reports Third Quarter 2019 Financial Results
2019-10-30 11:03 ET
Natera Announces Third Quarter 2019 Earnings Conference Call
2019-10-17 02:00 ET
Natera Announces Pricing of Follow-On Offering
2019-10-15 21:46 ET
Natera Launches Proposed Follow-On Offering
2019-10-03 12:45 ET
Natera to Host Investor Conference Call to Discuss Progress in its Oncology Business
2019-09-09 15:01 ET
Natera Publishes Largest NIPT Outcomes Study Demonstrating Robust Clinical Performance Over a 4-year Period
2019-09-04 13:03 ET
Natera to Present at the Morgan Stanley 17th Annual Global Healthcare Conference
2019-08-29 13:16 ET
Natera Appoints Rowan Chapman to its Board of Directors
2019-08-28 13:43 ET
Natera to Webcast Live Presentation at the Baird 2019 Global Healthcare Conference
2019-08-22 17:13 ET
Medicare Issues Positive Draft Local Coverage Determination for Natera's Signatera(TM) MRD Test in Colorectal Cancer
2019-08-22 13:16 ET
Panorama NIPT Achieves 2 Million Test Milestone
2019-08-07 20:07 ET
Natera Reports Second Quarter 2019 Financial Results
2019-08-05 12:02 ET
Publication Demonstrates Unique Ability of Panorama Test to Determine Zygosity in Twin Pregnancies
2019-08-01 00:51 ET
Natera Announces Second Quarter 2019 Earnings Conference Call
2019-05-06 15:55 ET
FDA Grants Breakthrough Device Designation to Natera's Signatera Test
2019-05-03 00:51 ET
Natera Announces First Quarter 2019 Earnings Conference Call
2019-04-18 03:43 ET
Natera Announces Pricing of Follow-On Offering
2019-04-16 20:12 ET
Natera Launches Proposed Follow-On Offering
2019-04-16 14:13 ET
New Publication Validates Clinical Performance of Signatera for Recurrence Monitoring and MRD Assessment in Breast Cancer
2019-04-10 12:03 ET
Natera Announces Plans to Commercialize Tumor Whole Exome Sequencing from Plasma
2019-03-28 16:46 ET
Medicare Issues Draft Local Coverage Determination for Natera's New Prospera(TM) Kidney Transplant Rejection Test

SEC forms

Show financial reports only

SEC form 8
2026-05-07 20:10 ET
Natera published news for 2026 q1
SEC form 8
2026-05-07 20:10 ET
Natera published news for 2026 q1
SEC form 8
2026-05-07 20:10 ET
Natera published news for 2026 q1
SEC form 8
2026-02-26 16:06 ET
Natera published news for 2025 q4
SEC form 8
2026-02-26 16:06 ET
Natera reported for 2025 q4
SEC form 8
2026-02-26 16:06 ET
Natera published news for 2025 q4
SEC form 8
2025-11-06 16:08 ET
Natera published news for 2025 q3
SEC form 8
2025-11-06 16:08 ET
Natera reported for 2025 q3
SEC form 8
2025-11-06 16:08 ET
Natera published news for 2025 q3
SEC form 10
2025-08-08 00:24 ET
Natera reported for 2025 q2
SEC form 8
2025-08-07 20:12 ET
Natera published news for 2025 q2
SEC form 8
2025-08-07 20:12 ET
Natera published news for 2025 q2
SEC form 8
2025-08-07 20:12 ET
Natera published news for 2025 q2
SEC form 10
2025-05-09 00:00 ET
Natera published news for 2025 q1
SEC form 10
2025-05-08 23:35 ET
Natera published news for 2025 q1
SEC form 8
2025-05-08 20:15 ET
Natera published news for 2025 q1
SEC form 8
2025-05-08 20:15 ET
Natera reported for 2025 q1
SEC form 8
2025-05-08 20:15 ET
Natera published news for 2025 q1
SEC form 10
2025-02-28 02:43 ET
Natera published news for 2024 q4
SEC form 10
2025-02-28 00:00 ET
Natera published news for 2024 q4
SEC form 8
2025-02-27 16:10 ET
Natera published news for 2024 q4
SEC form 8
2025-02-27 16:10 ET
Natera reported for 2024 q4
SEC form 8
2025-02-27 16:10 ET
Natera published news for 2024 q4
SEC form 8
2025-01-13 00:00 ET
Natera published news for 2024 q4
SEC form 8
2025-01-13 00:00 ET
Natera published news for 2024 q4
SEC form 10
2024-11-12 16:23 ET
Natera reported for 2024 q3
SEC form 8
2024-11-12 16:10 ET
Natera published news for 2024 q3
SEC form 8
2024-11-12 16:10 ET
Natera published news for 2024 q3
SEC form 8
2024-11-12 16:10 ET
Natera published news for 2024 q3
SEC form 10
2024-11-12 00:00 ET
Natera published news for 2024 q3
SEC form 10
2024-08-09 00:00 ET
Natera published news for 2024 q2
SEC form 10
2024-08-08 20:28 ET
Natera reported for 2024 q2
SEC form 8
2024-08-08 16:11 ET
Natera published news for 2024 q2
SEC form 8
2024-08-08 16:11 ET
Natera published news for 2024 q2
SEC form 8
2024-08-08 16:11 ET
Natera published news for 2024 q2
SEC form 10
2024-05-10 00:00 ET
Natera published news for 2024 q1
SEC form 8
2024-05-09 00:00 ET
Natera published news for 2024 q1
SEC form 8
2024-05-09 00:00 ET
Natera published news for 2024 q1
SEC form 8
2024-05-09 00:00 ET
Natera published news for 2024 q1
SEC form 10
2024-02-29 00:00 ET
Natera published news for 2023 q4
SEC form 10
2024-02-28 21:10 ET
Natera published news for 2023 q4
SEC form 8
2024-02-28 16:11 ET
Natera published news for 2023 q4
SEC form 8
2024-02-28 16:11 ET
Natera published news for 2023 q4
SEC form 8
2024-02-28 16:11 ET
Natera published news for 2023 q4
SEC form 8
2024-01-09 00:00 ET
Natera published news for 2023 q4
SEC form 8
2024-01-09 00:00 ET
Natera published news for 2023 q4
SEC form 8
2024-01-09 00:00 ET
Natera published news for 2023 q4
SEC form 10
2023-11-09 00:00 ET
Natera published news for 2023 q3
SEC form 10
2023-11-08 20:15 ET
Natera published news for 2023 q3
SEC form 8
2023-11-08 16:12 ET
Natera reported for 2023 q3
SEC form 10
2023-08-04 00:00 ET
Natera published news for 2023 q2
SEC form 10
2023-08-03 19:37 ET
Natera published news for 2023 q2
SEC form 6
2023-08-03 16:10 ET
Natera reported for 2023 q2
SEC form 8
2023-08-03 00:00 ET
Natera published news for 2023 q2
SEC form 6
2023-06-15 16:22 ET
Natera published news for 2023 q1
SEC form 10
2023-05-10 00:00 ET
Natera published news for 2023 q1
SEC form 8
2023-05-09 00:00 ET
Natera published news for 2023 q1
SEC form 6
2023-03-10 20:28 ET
Natera published news for 2022 q4
SEC form 6
2023-03-10 16:47 ET
Natera published news for 2022 q4
SEC form 10
2023-03-01 06:05 ET
Natera reported for 2022 q4
SEC form 10
2023-03-01 00:00 ET
Natera reported for 2022 q4
SEC form 6
2023-02-28 16:12 ET
Natera published news for 2022 q4
SEC form 8
2023-02-28 00:00 ET
Natera reported for 2022 q4
SEC form 6
2023-02-23 11:01 ET
Natera published news for 2022 q4
SEC form 6
2022-11-16 17:04 ET
Natera published news for 2022 q3
SEC form 10
2022-11-09 00:00 ET
Natera reported for 2022 q3
SEC form 10
2022-11-08 21:22 ET
Natera reported for 2022 q3
SEC form 6
2022-11-08 16:11 ET
Natera published news for 2022 q3
SEC form 8
2022-11-08 00:00 ET
Natera reported for 2022 q3
SEC form 6
2022-08-15 16:02 ET
Natera published news for 2022 q2
SEC form 10
2022-08-05 00:00 ET
Natera reported for 2022 q2
SEC form 10
2022-08-04 21:45 ET
Natera reported for 2022 q2
SEC form 6
2022-08-04 16:13 ET
Natera published news for 2022 q2
SEC form 8
2022-08-04 00:00 ET
Natera reported for 2022 q2
SEC form 6
2022-06-01 21:05 ET
Natera published news for 2022 q1
SEC form 6
2022-06-01 21:05 ET
Natera published news for 2022 q1
SEC form 6
2022-06-01 17:00 ET
Natera published news for 2022 q1
SEC form 6
2022-05-27 21:46 ET
Natera published news for 2022 q1
SEC form 6
2022-05-27 21:46 ET
Natera published news for 2022 q1
SEC form 6
2022-05-27 21:46 ET
Natera published news for 2022 q1
SEC form 6
2022-05-27 21:45 ET
Natera published news for 2022 q1
SEC form 6
2022-05-27 21:45 ET
Natera published news for 2022 q1
SEC form 6
2022-05-27 21:45 ET
Natera published news for 2022 q1
SEC form 10
2022-05-06 06:04 ET
Natera reported for 2022 q1
SEC form 10
2022-05-06 00:00 ET
Natera reported for 2022 q1
SEC form 6
2022-05-05 16:13 ET
Natera published news for 2022 q1
SEC form 8
2022-05-05 00:00 ET
Natera reported for 2022 q1
SEC form 6
2022-04-25 21:05 ET
Natera published news for 2022 q1
SEC form 6
2022-04-25 21:05 ET
Natera published news for 2022 q1
SEC form 6
2022-04-25 21:05 ET
Natera published news for 2022 q1
SEC form 6
2022-04-15 20:05 ET
Natera published news for 2022 q1
SEC form 6
2022-04-14 19:40 ET
Natera published news for 2022 q1
SEC form 6
2022-04-13 16:00 ET
Natera published news for 2022 q1
SEC form 6
2022-03-14 07:30 ET
Natera published news for 2021 q4
SEC form 10
2022-02-25 00:00 ET
Natera published news for 2021 q4
SEC form 10
2022-02-24 21:13 ET
Natera published news for 2021 q4
SEC form 6
2022-02-24 16:09 ET
Natera published news for 2021 q4
SEC form 8
2022-02-24 00:00 ET
Natera published news for 2021 q4
SEC form 10
2021-11-05 00:00 ET
Natera published news for 2021 q3
SEC form 10
2021-11-04 21:50 ET
Natera published news for 2021 q3
SEC form 6
2021-11-04 16:16 ET
Natera published news for 2021 q3
SEC form 8
2021-11-04 00:00 ET
Natera published news for 2021 q3
SEC form 10
2021-08-06 00:00 ET
Natera published news for 2021 q2
SEC form 10
2021-08-05 21:50 ET
Natera published news for 2021 q2
SEC form 6
2021-08-05 16:10 ET
Natera published news for 2021 q2
SEC form 8
2021-08-05 00:00 ET
Natera published news for 2021 q2
SEC form 6
2021-07-22 17:20 ET
Natera published news for 2021 q2
SEC form 6
2021-07-20 16:29 ET
Natera published news for 2021 q2
SEC form 8
2021-07-20 00:00 ET
Natera published news for 2021 q2
SEC form 6
2021-05-28 16:01 ET
Natera published news for 2021 q1
SEC form 6
2021-05-10 17:10 ET
Natera published news for 2021 q1
SEC form 10
2021-05-07 00:00 ET
Natera published news for 2021 q1
SEC form 10
2021-05-06 21:36 ET
Natera published news for 2021 q1
SEC form 6
2021-05-06 16:08 ET
Natera published news for 2021 q1
SEC form 8
2021-05-06 00:00 ET
Natera published news for 2021 q1
SEC form 6
2021-04-23 21:34 ET
Natera published news for 2021 q1
SEC form 6
2021-04-13 17:25 ET
Natera published news for 2021 q1
SEC form 10
2021-02-25 21:55 ET
Natera published news for 2020 q4
SEC form 6
2021-02-25 16:10 ET
Natera published news for 2020 q4
SEC form 6
2020-11-23 17:04 ET
Natera published news for 2020 q3
SEC form 10
2020-11-05 21:37 ET
Natera published news for 2020 q3
SEC form 6
2020-11-05 16:24 ET
Natera published news for 2020 q3